PSNL - Personalis launches NEOPS a Neoantigen-based composite biomarker

Personalis ([[PSNL]] +2.9%) announces the launch of its proprietary Neoantigen Presentation Score (‘NEOPS’).NEOPS combines the tumor genomic and immune-related analytics of the Personalis® NeXT Platform™ to create a composite biomarker. NEOPS leverages Personalis’ recently-launched machine learning-based tool, Systematic HLA Epitope Ranking Pan Algorithm, which provides more accurate prediction of neoantigen presentation, a core mechanism in determining immunotherapy response.Data presented at the AACR virtual meeting in June demonstrated that NEOPS significantly outperformed tumor mutational burden in predicting response to anti-PD-L1 therapy in a cohort of late-stage, unresectable melanoma patients.

For further details see:

Personalis launches NEOPS, a Neoantigen-based composite biomarker